Nanofluidics Market Size, Share, and Trends

Nanofluidics Market (By Product Type: Nanofluidic-based Devices, Nanofluidic Components, Others; By Application: Drug Delivery, Point-of-care Diagnostics, Pharmaceutical and Biotechnology Research, Clinical Diagnostics, Others, By Material: Polymer, Silicone, Glass, Others) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2032

  • Last Updated : May 2023
  • Report Code : 2956
  • Category : Healthcare

Nanofluidics Market Size and Companies

The global nanofluidics market is surging, with an overall revenue growth expectation of hundreds of millions of dollars over the forecast period from 2023 to 2032.

Nanofluidics Market Size 2023 To 2032

Access our Healthcare Data Intelligence Tool with 10000+ Database, Visit: Towards Healthcare

Key Takeaways

  • North America is expected to contribute the maximum market share from 2023 to 2032.
  • Asia Pacific is expected to expand at the fastest CAGR between 2023 and 2032.
  • By Product Type, the nanofluidics component segment is predicted to dominate the market from 2023 to 2032.
  • By Application, the point-of-care diagnostics segment is expected to expand at the fastest CAGR from 2023 to 2032.

Nanofluidics Market Overview

The study of fluids contained in structures with nanometric dimensions (usually 1–100 nm) is known as nanofluidics. Because of the high surface-to-bulk ratio, fluids contained in these structures show behaviors that are not seen in bigger structures. Technically speaking, nanofluidics is not a new area of study and has existed implicitly in many fields, but it has only lately been given a name of its own. Recent technological advancements have made it feasible to influence what happens at these scales, which has led to this evolution.

Additionally, improvements in observation and measurement methods now make it possible to measure the minute physical quantities that are peculiar to nanoscale systems. It would be erroneous to view nanofluidics as an extension of microfluidics, despite the fact that it was born in the wake of microfluidics. In fact, whereas in microfluidics the only scale that matters is the system size, in nanofluidics a wide range of characteristic lengths that produce coupled phenomena and give rise to complicated fluid behaviors must be taken into account.

Furthermore, because nanofluidics is at the convergence of physics, chemistry, and biology, it has implications for a wide range of fields, including physiology, membrane science, thermodynamics, and colloidal science. Consequently, nanofluidics research frequently requires an interdisciplinary approach.

The market growth is being driven by various factors such as growing investment in nanotechnology across the industry, increasing cases of cancer across the globe, growing pharmaceutical and biotechnology industry, and growing adoption of nanofluidics platforms for immunotherapy.

  • According to estimates from the International Agency for Research on Cancer (IARC), there were 9.5 million cancer-related deaths and 17.0 million new cases of cancer worldwide in 2018.

Nanofluidics Market Scope

Report Coverage Details
Largest Market North America
Fastest Growing Market Asia Pacific
Base Year 2022
Forecast Period 2023 to 2032
Segments Covered By Product Type, By Application, and By Material
Regions Covered North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa


Nanofluidics Market Dynamics

Driver:

Growing prevalence of cancer across the globe

The growing prevalence of cancer across the globe is expected to drive the growth of the market over the forecast period. For cell biology, disease pathology, drug development, and medical treatment, living single-cell investigation is essential. Finding the law of the universe and learning how serious diseases occur are very important. To obtain the average information about cells, the traditional single analysis concentrates on a large number of cells or cell lysis.

As a result, it is unable to assess the ongoing, real-time data on variations between individual cells, which restricts the growth of numerous industries, including the biomedical one. Small sample volumes, quick turnaround times, easy operation, and efficient processing, which have been widely used in complex operations like single cell capture, separation, and detection, distinguish nanofluidics-based biochemical analysis from conventional methods. Thus, the increasing incidence of cancer is anticipated to drive the demand for nanofluidics.

For instance, according to the International Agency for Research on Cancer, one of the main causes of death in the globe is cancer. In 2018, there were 18.1 million new instances of cancer and 9.5 million cancer-related deaths worldwide. By 2040, it is predicted that there will be 29.5 million new cases of cancer per year and 16.4 million cancer-related deaths.

Restraints:

Stability of nanofluids

The stability of nanofluids is one of the major drawbacks that hinder market growth over the forecast period. Nanofluids lose their capacity to conduct heat because of their propensity to aggregate. For the evaluation of nanofluids that can alter their thermophysical properties for applications, their stability is a crucial factor. Utilizing physical (ultrasonic agitation, homogenization, and ball milling) and chemical (surfactant addition, surface modification, and pH correction) methods, the long-term stability and thermal properties of the nanofluids were improved. Thus, during the projection period, the stability of nanofluids may be impeding market expansion.

Opportunities:

The growing application of nanofluidics in immunotherapy

A newer form of treatment called immunotherapy strengthens the body's natural defenses against diseases like cancer. Cell-based therapeutics, cancer vaccines, and monoclonal antibodies checkpoint inhibitors are the three main categories of cancer immunotherapy. Engineered T cells and nanoscale extracellular vesicles are frequently used in cell-based immunotherapy and tailored therapeutics as a result of advancements in biotechnology and a better understanding of immune oncology.

As cutting-edge tools for cell/EV engineering, single-cell manipulation and analysis, as well as the investigation of the tumor microenvironment, microfluidics and nanofluidics platforms uniquely provide advantages. Thus, the growing adoption of nanotechnology in immunotherapy is expected to offer an enormous opportunity for market expansion during the forecast period.

Product Type Insights

Based on the product type, the global nanofluidics market is segmented into nanofluidic-based devices, nanofluidic components, and others. The nanofluidics component is expected to dominate the market during the forecast period. The nanofluidics segment is further classified into nanofluidic chips, nano pumps, nanoneedles and others. Nanofluidic chips are expected to grow at a significant rate during the forecast period.

The use of nanofluidic chips enables the study of nanofluids under a variety of flow conditions with little to no pressure shockwave interference and no viewing window distortion. Thus, owing to these properties of the nanofluidics chip system are expected to drive the growth of the market over the forecast period. Nanopumps is expected to grow at the fastest rate over the forecast period. The growth in the segment is owing to the use of these devices to detect DNA sequencing. A tool for locating a target nucleic acid sequence contained in a mixture of nucleic acid fragments and having a chosen pH is also included in the invention. Thus, this is expected to drive the segmental growth during the forecast period.

Application Insights

Based on the application, the global nanofluidics market is divided into drug delivery, point-of-care diagnostics, pharmaceutical and biotechnology research, clinical diagnostics and others. The point-of-care diagnostics is expected to grow at the highest CAGR over the forecast period. Through the combined impact of effective mass transfer and low diffusion distances, protein sensing in a nanofluidic environment drastically reduces the time it takes for an immunoassay to provide a result.

The use of in vitro diagnostic (IVD) testing at the point of care is spreading among medical practitioners worldwide. In fact, compared to laboratory tests, their quick turnaround times allow for quicker disease diagnosis, monitoring, and clinical management decisions.

This significant advantage makes them particularly helpful in clinical emergencies, such as acute heart failure and myocardial infarction, acute respiratory illness, and septic shock. However, the advantage of utilizing near-patient environmental conditions and on-the-spot biomarker measurement to speed up clinical decision-making is only valid if technical, analytical, and diagnostic performances are comparable to those of the equivalent tests carried out in a controlled laboratory setting. Thus, this factor drives the segment growth during the forecast period.

Regional Insights

North America is expected to capture the largest market share over the forecast period. The growth in the region is attributed to the growing pharmaceutical and biotechnology industry. For instance, according to the Biotechnology Innovation Organization (BIO) and the Council of State Bioscience Associations (CSBA), it is estimated that the US bioscience industry was valued at 2.9 trillion dollars in 2021. In addition, they also revealed that the US industry employed 2.1 million people in over 127,000 businesses. Moreover, the increasing R&D for proteomics research in the region also provides an enormous opportunity for market expansion. For instance, in July 2021, the United States NIH invested around USD 20 million in technology development in single-molecule and single-cell proteomics.

Nanofluidics Market Share, By Region, 2022 (%)

This increases the research activities on proteomics in the country, in turn, penetrates the market. Furthermore, the robust healthcare infrastructure and the growing use of the nanofluidic system for cancer research are expected to propel the market. The cancer cases in the region are very high including lung cancer, pancreatic cancer, breast cancer and others. According to a recent analysis of data from the National Program of Cancer Registries database, which includes information on about 65% of the US population, the incidence of pancreatic cancer is rising more quickly in women than in men under the age of 55 and among people 55 and older.

The Asia Pacific is expected to grow at the fastest rate during the forecast period. The regional growth is attributed to the growing government initiatives and the growing incidence of chronic diseases such as cardiovascular, cancer, and others. For instance, in rural and urban areas, respectively, cardiovascular disease (CVD) caused 46.74% and 44.26% of all fatalities in 2019. CVD was the cause of two out of every five fatalities. In China, there are thought to be 330 million CVD patients.

The incidence of pancreatic cancer in India is also 0.5-2.4 per 100,000 men and 0.2-1.8 per 100,000 women, according to the secondary analysis. Furthermore, the increasing healthcare industry in the region is one of the key factors that propel the market growth during the study period.

Nanofluidics Market Companies

  • miDiagnostics
  • Heidelberg Instruments
  • ZEISS Microscopy
  • Illumina, Inc.
  • Agilent Technologies 
  • Caliper Life Sciences
  • Cepheid
  • Danaher Corporation
  • Bio-Rad Laboratories, Inc.
  • Abbott
  • F. Hoffmann-La Roche Ltd
  • Fluidigm Corporation

Segments Covered in the Report:

By Product Type

  • Nanofluidic-based Devices
  • Nanofluidic Components
    • Nanofluidic Chips
    • Nano Pumps
    • Nanoneedles
    • Others
  • Others

By Application

  • Drug Delivery
  • Point-of-care Diagnostics
  • Pharmaceutical and Biotechnology Research
    • High-throughput Screening
    • Proteomics
    • Genomics
    • Cell-based Assay
    • Capillary Electrophoresis
    • Others
  • Clinical Diagnostics
  • Others

By Material

  • Polymer
  • Silicone
  • Glass
  • Others

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

Frequently Asked Questions

The major players operating in the nanofluidics market are miDiagnostics, Heidelberg Instruments, ZEISS Microscopy, Illumina, Inc., Agilent Technologies, Caliper Life Sciences, Cepheid, Danaher Corporation, Bio-Rad Laboratories, Inc., Abbott, F. Hoffmann-La Roche Ltd, Fluidigm Corporation, and Others.

The driving factors of the nanofluidics market are the growing investment in R&D, growing incidence of cancer, growing drug delivery, and increasing demand for advanced technology for analyzing the structures of cells.

North America region will lead the global nanofluidics market during the forecast period 2023 to 2032.

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Nanofluidics Market 

5.1. COVID-19 Landscape: Nanofluidics Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Nanofluidics Market, By Product Type

8.1. Nanofluidics Market, by Product Type, 2023-2032

8.1.1 Nanofluidic-based Devices

8.1.1.1. Market Revenue and Forecast (2020-2032)

8.1.2. Nanofluidic Components

8.1.2.1. Market Revenue and Forecast (2020-2032)

8.1.3. Others

8.1.3.1. Market Revenue and Forecast (2020-2032)

Chapter 9. Global Nanofluidics Market, By Application

9.1. Nanofluidics Market, by Application, 2023-2032

9.1.1. Drug Delivery

9.1.1.1. Market Revenue and Forecast (2020-2032)

9.1.2. Point-of-care Diagnostics

9.1.2.1. Market Revenue and Forecast (2020-2032)

9.1.3. Pharmaceutical and Biotechnology Research

9.1.3.1. Market Revenue and Forecast (2020-2032)

9.1.4. Clinical Diagnostics

9.1.4.1. Market Revenue and Forecast (2020-2032)

9.1.5. Others

9.1.5.1. Market Revenue and Forecast (2020-2032)

Chapter 10. Global Nanofluidics Market, By Material 

10.1. Nanofluidics Market, by Material, 2023-2032

10.1.1. Polymer

10.1.1.1. Market Revenue and Forecast (2020-2032)

10.1.2. Silicone

10.1.2.1. Market Revenue and Forecast (2020-2032)

10.1.3. Glass

10.1.3.1. Market Revenue and Forecast (2020-2032)

10.1.4. Others

10.1.4.1. Market Revenue and Forecast (2020-2032)

Chapter 11. Global Nanofluidics Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Product Type (2020-2032)

11.1.2. Market Revenue and Forecast, by Application (2020-2032)

11.1.3. Market Revenue and Forecast, by Material (2020-2032)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Product Type (2020-2032)

11.1.4.2. Market Revenue and Forecast, by Application (2020-2032)

11.1.4.3. Market Revenue and Forecast, by Material (2020-2032)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Product Type (2020-2032)

11.1.5.2. Market Revenue and Forecast, by Application (2020-2032)

11.1.5.3. Market Revenue and Forecast, by Material (2020-2032)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Product Type (2020-2032)

11.2.2. Market Revenue and Forecast, by Application (2020-2032)

11.2.3. Market Revenue and Forecast, by Material (2020-2032)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Product Type (2020-2032)

11.2.4.2. Market Revenue and Forecast, by Application (2020-2032)

11.2.4.3. Market Revenue and Forecast, by Material (2020-2032)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Product Type (2020-2032)

11.2.5.2. Market Revenue and Forecast, by Application (2020-2032)

11.2.5.3. Market Revenue and Forecast, by Material (2020-2032)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Product Type (2020-2032)

11.2.6.2. Market Revenue and Forecast, by Application (2020-2032)

11.2.6.3. Market Revenue and Forecast, by Material (2020-2032)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Product Type (2020-2032)

11.2.7.2. Market Revenue and Forecast, by Application (2020-2032)

11.2.7.3. Market Revenue and Forecast, by Material (2020-2032)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Product Type (2020-2032)

11.3.2. Market Revenue and Forecast, by Application (2020-2032)

11.3.3. Market Revenue and Forecast, by Material (2020-2032)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Product Type (2020-2032)

11.3.4.2. Market Revenue and Forecast, by Application (2020-2032)

11.3.4.3. Market Revenue and Forecast, by Material (2020-2032)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Product Type (2020-2032)

11.3.5.2. Market Revenue and Forecast, by Application (2020-2032)

11.3.5.3. Market Revenue and Forecast, by Material (2020-2032)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Product Type (2020-2032)

11.3.6.2. Market Revenue and Forecast, by Application (2020-2032)

11.3.6.3. Market Revenue and Forecast, by Material (2020-2032)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Product Type (2020-2032)

11.3.7.2. Market Revenue and Forecast, by Application (2020-2032)

11.3.7.3. Market Revenue and Forecast, by Material (2020-2032)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Product Type (2020-2032)

11.4.2. Market Revenue and Forecast, by Application (2020-2032)

11.4.3. Market Revenue and Forecast, by Material (2020-2032)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Product Type (2020-2032)

11.4.4.2. Market Revenue and Forecast, by Application (2020-2032)

11.4.4.3. Market Revenue and Forecast, by Material (2020-2032)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Product Type (2020-2032)

11.4.5.2. Market Revenue and Forecast, by Application (2020-2032)

11.4.5.3. Market Revenue and Forecast, by Material (2020-2032)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Product Type (2020-2032)

11.4.6.2. Market Revenue and Forecast, by Application (2020-2032)

11.4.6.3. Market Revenue and Forecast, by Material (2020-2032)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Product Type (2020-2032)

11.4.7.2. Market Revenue and Forecast, by Application (2020-2032)

11.4.7.3. Market Revenue and Forecast, by Material (2020-2032)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Product Type (2020-2032)

11.5.2. Market Revenue and Forecast, by Application (2020-2032)

11.5.3. Market Revenue and Forecast, by Material (2020-2032)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Product Type (2020-2032)

11.5.4.2. Market Revenue and Forecast, by Application (2020-2032)

11.5.4.3. Market Revenue and Forecast, by Material (2020-2032)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Product Type (2020-2032)

11.5.5.2. Market Revenue and Forecast, by Application (2020-2032)

11.5.5.3. Market Revenue and Forecast, by Material (2020-2032)

Chapter 12. Company Profiles

12.1. miDiagnostics

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Heidelberg Instruments

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. ZEISS Microscopy

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Illumina, Inc.

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Agilent Technologies

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Caliper Life Sciences

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Cepheid

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Danaher Corporation

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Bio-Rad Laboratories, Inc.

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Abbott

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Proceed To Buy

USD 4900
USD 3800
USD 2100
USD 2100
USD 7500

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client